Quark Venture Inc
Quark Venture is a Canadian-based venture capital investment firm. Established in 2015, Quark Venture invests in innovative biotechnology and health technology companies and supports them with its expertise in bioscience commercialization and equity financing. The company’s strategic focus is global investments in disruptive platforms and technologies impacting human health. Our strategic goal is to support and enable companies we invest in to grow, create value and be successful by providing not only financial support, but also developmental, infrastructure and expertise support, as needed, through our global network. Quark Venture is currently investing out of a US$500 million Global Health Sciences Venture Fund that it co-GP’s GF Securities Company Limited, a leading investment bank in China. Fifteen investments have been made to date
Through its China affiliate, the Global Drug Commercialization Center (GDCC), Quark’s leading-edge Development Centre and SME Accelerator in China, Quark also helps small- and medium-size enterprises successfully access the China market to grow, innovate and bring better health outcomes to millions of people
Conference Objective
Identify potential investment opportunities & Identify potential syndicate partners (VC’s, corporate VC’s, foundations)
Delegate Contacts
In her role as CEO & Partner at Quark Venture Ms. Es Sabar is also a Director of the $500 million Global Health Sciences Fund (GHS Fund), which was co-established with GF Securities, Hong Kong. Quark is a Canadian-based venture capital investment firm (headquartered in Vancouver) that focuses on equity financing in biotechnology and health sciences companies. Prior to joining Quark Venture, Ms. Es Sabar led the Centre for Drug Research and Development (CDRD) as Canada’s national translation centre. She has an expansive global career spanning multi-national pharmaceutical/biotechnology companies (most notably Sanofi Pasteur), start-ups, not-for-profit organizations and venture investment. Ms. Es Sabar has received multiple awards and recognitions for her pioneering work, including Canada’s Most Powerful Women: Top 100 Award. She holds an Executive Certificate in Management and Leadership from the MIT Sloan School of Management; an MSc degree in Neurochemistry from the Institute of Psychiatry University of London, England ‒ and a BSc Joint Honours degree in Biochemistry/Chemistry from the University of Salford in Manchester, England.
Kaley is the Director of Business Development at Quark Venture, a global venture capital investment firm headquartered in Vancouver, Canada. She is also currently interim CEO of Quark Venture’s portfolio company, ARTMS Products Inc., a leader in the development of novel technologies and products which enable the production of the world’s most-used diagnostic imaging isotope, technetium‐99m (Tc‐99m), using local, hospital-based medical cyclotrons. In her previous role as Associate Director, Partnerships, at the Centre for Drug Research and Development, she played a key role in building and maintaining the organization’s strategic alliances and partnerships with industry, academia, government and foundations. Dr. Wilson also lead the identification and evaluation of drug discovery projects with potential therapeutic value in the areas of infection, inflammation and immunity — her areas of scientific expertise. Dr. Wilson obtained her PhD at the University of British Columbia (UBC), Canada. During her Ph.D. Dr Wilson was the recipient of a number of prestigious scholarships and awards from CIHR, NSERC and the MSFHR.